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Abstract
Hepatitis B virus (HBV), along with Hepatitis C virus chronic infection, represents a major risk factor for
hepatocellular carcinoma (HCC) development. However, molecular mechanisms involved in the development of
HCC are not yet completely understood. Recent studies have indicated that mutations in CTNNB1 gene encoding
for β-catenin protein lead to aberrant activation of the Wnt/ β-catenin pathway. The mutations in turn activate
several downstream genes, including c-Myc, promoting the neoplastic process. The present study evaluated the
mutational profile of the CTNNB1 gene and expression levels of CTNNB1 and c-Myc genes in HBV-related HCC, as
well as in cirrhotic and control tissues. Mutational analysis of the β-catenin gene and HBV genotyping were
conducted by direct sequencing. Expression of β-catenin and c-Myc genes was assessed using real-time PCR.
Among the HCC cases, 18.1% showed missense point mutation in exon 3 of CTNNB1, more frequently in codons 32,
33, 38 and 45. The frequency of mutation in the hotspots of exon 3 was significantly higher in non-viral HCCs
(29.4%) rather than HBV-related cases (12.7%, P = 0.021). The expression of β-catenin and c-Myc genes was found
upregulated in cirrhotic tissues in association with HBV infection. Mutations at both phosphorylation and
neighboring sites were associated with increased activity of the Wnt pathway. The results demonstrated that
mutated β-catenin caused activation of the Wnt pathway, but the rate of CTNNB1 gene mutations was not related
to HBV infection. HBV factors may deregulate the Wnt pathway by causing epigenetic alterations in the HBV-related
HCC.
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Introduction
Hepatocellular carcinoma (HCC) is the most occurring
malignancy of the liver and with 782,000 new cases an-
nually and 600,000 deaths/year globally accounts for at
least 75% of all liver cancer cases [1, 2]. Major risk fac-
tors are chronic infections with Hepatitis B Virus (HBV)
and Hepatitis C Virus (HCV), alcohol, aflatoxin and fatty
liver diseases; however, HBV is implicated as the most
common etiological agent of HCC worldwide [2, 3]. The
highest incidence of HCC is seen in Eastern Asian coun-
tries followed by the Asian-Pacific region, and these re-
gions have high rates of HBV and HCV. Hepatic
carcinogenesis is a multistep process characterized by
multiple genetic alterations whose mechanisms are not
fully understood [1, 2].
Genetic mutations and aberrant activation of signal
transduction pathways play important roles in the devel-
opment of HCC. It has been confirmed that several sig-
naling pathways are aberrantly activated in HCC
development [4]. Among these, the Wnt/β-catenin path-
way seems to play a pivotal role in initiating and sustain-
ing HCC development [5].
In the canonical Wnt pathway, β-catenin is the main
effector normally sequestered by the destruction com-
plex [6]. In the absence of Wnt ligands, β-catenin is
phosphorylated by GSK3β, and subsequently ubiquiti-
nated and degraded in the proteasome [7]. However, in
the presence of ligands (Wnt proteins), Wnts interact
with receptors (FZDs) and co-receptor molecules (LRP5/
6), thereby disassembling the destruction complex [8].
This signal leads to cytoplasmic stabilization of β-
catenin and then nuclear transport of β-catenin. In the
nucleus, β-catenin triggers activation and transcription
of downstream target genes through conjunction with
TCF/LEF DNA binding proteins. Next, the consequence
is stimulation of target genes involved in the cell prolif-
eration and/or carcinogenesis with their proto-
oncogenic effect. Wnt target genes include c-Myc, cyclin
D1, CTGF, WISP2 and c-fus, among which upregulation
of c-Myc leads to proto-oncogenic effect in liver malig-
nancies [8–10].
Mutations in the β-catenin gene are in association
with the development of several human cancers, includ-
ing HCC [11–13]. Alterations in phosphorylation targets
in the N-terminal domain of β-catenin prevents the
phosphorylation of β-catenin and subsequent proteaso-
mal degradation. This leads to cytoplasmic accumulation
of β-catenin, which in turn translocates to the nucleus
and stimulates the transcription of Wnt target genes in-
volved in apoptosis and proliferation [6].
Genetic alteration in liver malignancies shows di-
verse patterns in different geographical regions
which is most likely linked to risk factors and muta-
tions in human genes [12, 14]. For example,
according to the COSMIC database CTNNB1 muta-
tion rate is higher in Europe and Americas than in
Asia [12]. Several investigations have addressed the
association of CTNNB1 mutations in HCV-associated
HCCs [12, 15, 16]. However, few studies with small
sample sizes have assessed CTNNB1 mutations in
HBV-related HCCs. Moreover, no data was available
regarding this pattern in the Middle East and Iran.
Therefore, we analyzed the mutational pattern of
CTNNB1 gene in a series of HBV positive HCC




Fifty-four fresh frozen (FF) tissues, comprising cases
of HCC, liver cirrhosis (LC) and normal histology
tissues, were taken by fine needle biopsies from pa-
tients attending hospitals affiliated with Iran Univer-
sity of Medical Sciences. Moreover, formalin fixed
paraffin embedded (FFPE) samples (n = 111) includ-
ing HCC, LC and non-tumor tissues were also retro-
spectively analyzed. Overall, 165 samples were
examined, including HBV positive HCC (n = 71),
non-virus related HCC (n = 34), liver cirrhosis (n =
28) and tissues with normal histology (n = 32).
Demographic and clinical information of the patients
are briefly shown in Table 1.
Archived samples were collected from March 2013
and FF samples from May 2017 to April 2019. The
FF and FFPE samples were histologically examined by
an expert pathologist for confirmation of HCC, LC or
normal histology. Informed consent was signed by
each patient, and the project was approved by the
ethical committee of research at IUMS under declar-
ation of Helsinki (Ethic code: IR.IUMS.FMD.REC
1396.9321540004).
Table 1 Demographic and clinical information of the studied
population
Characteristics HBV-HCC Non-viral HCC LC Normal liver
Number 71 34 28 32
Male 55 (77.5) 24 (70.6) 15 (53.6) 20 (62.5)
Female 16 (22.5) 10 (29.4) 13 (46.4) 12 (37.5)
Age
Mean 60.2 ± 12.4 59.2 ± 14.2 57.8 ± 13.6 50.5 ± 14.5
< 40 4 (5.6) 4 (11.8) 4 (14.3) 7 (21.9)
40–50 8 (11.3) 3 (8.8) 3 (10.7) 8 (25)
51–60 19 (26.8) 5 (14.7) 11 (39.3) 11 (34.4)
> 60 40 (56.3) 22 (64.7) 10 (35.7) 6 (18.8)
HBV+ 71 (100) 0 12 (42.8) 11 (34.4)
Cirrhosis 20 (28.2) 7 (20.6) 28 (100) –
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DNA extraction
DNA was isolated using tissue DNA extraction kit
(NucleoSpin® Tissue, Mini kit for DNA from cells and
tissue, Macherey-Nagel Co, Germany) according to the
kit instructions with the use of 1 mg of liver tissue. For
each FFPE sample, 10 cuts with 15 μm thickness were
first underwent for paraffin removal using xylene and
ethanol, and then 1mg of obtained tissue was forwarded
in the above DNA isolation kit. The concentration and
purity of isolated DNA were checked by BioPhotometer
(NanoDrop 1000 Spectrophotometer, Thermo Fisher
Scientific, United States) and running in agarose gel.
RNA extraction and synthesis of cDNA
Isolation of total RNA from FF samples was performed
using a tissue RNA extraction kit (NucleoSpin® total
RNA, MN, Macherey-Nagel Co, Germany). For each
FFPE samples, 10 cuts with 10 μm thickness were sub-
jected for paraffin removal. We performed additional
processing steps to improve RNA extraction from FFPE
as described in the supplementary method. Then, the
processed samples were used for RNA extraction with
the above-mentioned kit. The purity and concentration
of obtained RNA were checked by a BioPhotometer
(The ratio of 260/280 was optimized between 1.7–2).
The concentration and integrity of RNA were observed
on agarose gel (Supplementary Figure 1). For gene ex-
pression assays, RNA samples were first treated with
DNase I (Yekta Tajhiz Azma, YTA, Iran), and then
DNase treated RNAs were applied to synthesize cDNA
using random hexamer primers in the procedure of the
First Strand cDNA Synthesis Kit (Fermentas, Thermo
Fisher Scientific TR Limited, Waltham, Massachusetts,
United States).
Identification of mutations in CTNNB1 gene
Several standard PCR assays were designed to identify β-
catenin mutations. In all PCR assays of this study,
necessary care was taken to avoid any carry over con-
tamination. All the primers used in this study were syn-
thesized and purchased from Metabion Company
(Metabion international AG, Planegg/Steinkirchen,
Germany, Table 2).
A single step PCR was designed to amplify exons 3 to
5 (Table 2). The thermal conditions were as follows: pre-
heat at 95 °C for 10 min, then 45 cycles of 94 °C for 15 s,
57 °C for 15 s, and 72 °C for 1 min for amplification a
994 base pair product. Moreover, a nested PCR ap-
proach was designed for whole exon 3 of the CTNNB1
gene (Table 2).
Determination of the expression levels of β-catenin and c-
Myc
To assess the active status of the Wnt pathway, the ex-
pression levels of β-catenin and c-Myc mRNAs were
evaluated using the SYBR green based real-time PCR
assay. Primers used in this section are given in Table 2.
All the RT- PCR programs were performed on a Rotor
Gene 3000 Real-Time PCR Machine using SYBR master
2X (2X SYBR® Green Real Time PCR Master Mix, Pars
Tous Biotechnology, Mashhad, Iran). Samples were
tested in duplicates and mean cycles of threshold (Ct)
was used for further analyses. Values were normalized
relative to the expression level of two internal house-
keeping genes (GAPDH and HMBS) [17]. The 2-ΔΔCt
formula was used for calculation of relative gene expres-
sion. In this way, ΔCt means Ct of target gene –mean Ct
of GAPDH and HMBS, and ΔΔCt is equal to tumor
ΔCt- normal sample ΔCt [19].
Genotyping of HBV
HBV infection of all samples was investigated using a
conventional PCR test, as previously described [18].
Table 2 presents the sequence of primers used; the
nested-PCR amplicon was a 417 bp segment corre-
sponding to the HBsAg coding region subsequently





PCR size Taa Ref
β-catenin CGTGGACAATGGCTACTCAA CACTCAGAGAAGGAGCTGTGG 150 57 b
c-Myc GGACGACGAGACCTTCATCAA CCAGCTTCTCTGAGACGAGCTT 92 60 [10]
HMBS CCCTGCCAGAGAAGAGTGTG GTGTTGAGGTTTCCCCGAAT 109 57 b
GAPDH CGACCACTTTGTCAAGCTCA AGGGGTCTACATGGCAACTG 228 58 [17]
HBS1 GAGTCTAGACTCGTGGTGGACTTC AAATKGCACTAGTAAACTGAGCCA 448 58 [18]
HBS2 CGTGGTGGACTTCTCTCA ATTTTC GCCARGAGAAACGGRCTGAGGCCC 417 60 [18]
CTNNB1 ex3–5 TAGCTGATTTGATGGAGTTGG CTCACGATGATGGGAAAGGT 994 57 b
CTNNB1 ex3, outer TGCTTTTCTTGGCTGTCTTTC CCTAAATGGTAAAAGTGACATTGC 500 55 b
CTNNB1 ex3, inner TGCTAATACTGTTTCGTATTTATAGC TTCTGACTTTCAGTAAGGCAATG 293 53 b
aTa is the temperature of annealing for each primer set
bThese primers were designed in current study
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subjected to direct sequencing for HBV genotyping.
The obtained sequence data were aligned with the
reference sequence of the accession number
GQ183486 for construction of the phylogenetic tree
using the MEGA software version 7.
Statistical analysis
The data were categorized in the SPSS package and
compared using chi-square, x2 test or Fisher’s exact
tests. Values lower than 0.05 were considered as signifi-
cant. Mann-Whitney and student t-test were used to
compare quantitative characters. The Graph Pad Prism




All samples were investigated for HBV-DNA, and 56.9%
were found to be positive for HBV; 71/105 (67.6%)
among HCC cases, 12/28 (42.8%) in the cirrhosis group
and 11/32 (34.4%) among liver samples with normal
histology (Table 1). In the HCC group, the HBV S gene
was partially sequenced and the nucleotide sequences
subjected to phylogenetic analysis (Data are not shown)
by using the MEGA software and also Geno2Pheno on-
line tool (https://hbv.geno2pheno.org/). The results
showed that all characterized samples belonged to the
HBV subgenotype D1.
Frequency of mutations in CTNNB1 gene
Exon 3 and exons 3–5 were amplified using a pfu
Taq-DNA polymerase (Yekta Tajhiz Azma, YTA, Iran)
(Supplementary Fig. 2), and subjected to sequencing
(Bioneer, South Korea). In exon 4, two point muta-
tions (Q85H and D145E) were found only in non-
viral HCC (Supplementary Fig. 3). In exon 5, there
were two point mutations (Q203H and E209Q); no
mutation was identified in both normal and LC
group.
Overall, 19/105 of HCC samples (18.1%) had at
least one non-synonymous mutation in the hotspot
region of β-catenin (Table 3, and Fig. 1). Known mu-
tations found in exon 3 were: D32V/G, S33C, H36Q,
S37C, G38V/S/R, A39V, T41P, T42A, P44R and S45P.
The majority of mutations was observed in codons 32
(n: 3), 38 (n: 3) and 45 (n: 3), in which serine was
the most affected amino acid (Fig. 2). No deletion or
insertion was identified in the studied regions. How-
ever, there were some other unknown missense and
nonsense mutations listed in the supplementary table.
Among LC and normal tissues, there was no muta-
tion in exon 3 of the β-catenin gene.
Mutations of CTNNB1 in association to HBV infection
The frequency of mutations in the hotspots of exon
3 was significantly higher in non-viral HCC rather
than HBV-related ones (P = 0.021). Overall, 9/71
(12.7%) of HBV-HCCs, and 10/34 (29.4%) in non-
viral HCCs had a mutation in the hotspot region of
β-catenin. Furthermore, the pattern of mutations was
also different between HBV-HCC and non-viral HCC
(Fig. 2). A mutation in codon 33 (S33C) was the
most prevalent mutation found in three HBV-HCC
samples. Some mutations were observed more preva-
lently in HBV-HCCs; S33C (n: 3), H36Q (n: 1), S37C
(n: 1) and A39V (n: 1); however, other mutations
were seen in both groups (S33C, P44R and S45P).
Tissues with non-viral HCC had a higher frequency
of mutation in codon 32, 38 and 45 rather than
HBV-related ones (5.8% vs 1.4% for each mutation).
Moreover, the type of amino acid change was also
different in these positions: G vs Y in 32 and R vs V
in 38 (Fig. 2). The frequency of mutation in codon
44 was equal, and the type of change was also simi-
lar in tumors with both etiologies (P44R). Neverthe-
less, T41I and T42A mutations were identified only
in non-viral tumors.
Determination of β-catenin expression level
The results of real-time PCR showed that the ex-
pression level of β-catenin was significantly higher
among the tumor samples than in the normal group
(Fig. 3, Fig. 4). Elevated levels of β-catenin and c-
Myc expression were observed also in cirrhotic
Table 3 CTNNB1 mutation in HCC cases according to
demographic and pathological characteristics
Characteristics CTNN mutation N (%) P
Male 14 (17.7) 0.575
Female 5 (19.2)
Age
40 > 1 (12.5) 0.034a
40–50 1 (9.1)
51–60 4 (16.6)
> 60 13 (21)
Differentiation





Yes 4 (14.8) 0.423
No 15 (19.2)
aThe frequency of mutations was significantly increased toward aging, bThe
rate of mutations in well differentiated tumors was higher than others
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samples (Fig. 3, Fig. 4). Higher levels of β-catenin
and c-Myc were found in the HBV-LC group than
non-viral-LC group; however, the expression level of
c-Myc was not statistically different between HBV-
HCC and non-viral HCC groups (Fig. 3).
Determination of the expression level of β-catenin in
association to mutations
Next, we aimed to determine whether the mutation phe-
notypes identified in HCC tumors were associated with
the activation of the Wnt pathway. Considering that c-
Fig. 1 Examples of representative sequence chromatograms of the identified mutations in the hotspot region of β-catenin gene. A: S33C, B:
H36Q, C: G38V, D: T42A, E: T41P, F: P44R
Fig. 2 Illustration of the location of N- terminal amino acids of β-catenin along with the profile of mutations identified in HBV-HCC and non-viral
HCC. Phosphorylation positions were marked with bold letters
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Myc is one of the target genes of this pathway [20], Wnt
activation was assessed by analyzing c-Myc expression
levels following normalization to the GAPDH gene.
Tumor samples harboring at least one missense muta-
tion in the hotspot region of β-catenin revealed significant
higher levels of c-Myc compared to wild type cases (Fig. 5).
Among different mutation sites identified in this study,
mutations at positions 32 and 45 were related to higher
levels of c-Myc. Moreover, it appeared that mutation in
both phosphorylation sites (32, 33, 36, 37, 41 and 45) as
well neighboring sites within the hotspot region (39 and
44) could result in upregulation of c-Myc (Fig. 5). Among
cases with mutation in exons 4 and 5, no significant differ-
ence was observed in term of gene expression (Fig. 5).
Discussion
Molecular mechanisms involved in the development of
HCC are not yet completely understood. This is partly
owing to different etiologies of HCC as well as genetic
heterogeneity of the patients. Overexpression and activa-
tion of β-catenin are now regarded as a frequent event
in the development of HCC, which may be caused by
mutations in the CTNNB1 gene as well as some other
epigenetic factors. Hence, we examined the mutation
status in exons 3–5 of the CTNNB1 gene and expression
level of β-catenin gene in association with HBV
infection.
Among HCC cases, we found two non-synonymous
nucleotide changes in exon 4 and two in exon 5 of
Fig. 3 The results of real-time PCR for β-catenin and c-Myc were analyzed in normalization to the mean expression level of GAPDH and HMBS
and in adjustment to the control group. The result showed that the expression of β-catenin and c-Myc was significantly upregulated among
cases with LC and HCC (a). The expression among HBV-HCC and non-viral HCC was not statistically different (b). The expression of these genes
showed elevated levels among HBV-LC (c). *: p < 0.05, **: p < 0.005, ***: p < 0.0005, ****: p < 0.00005
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CTNNB1 gene. These exons correspond to the N-
terminus domain of β-catenin that can be a phosphoryl-
ation site for GSK3β or casein kinase-1, and/or a binding
site for alpha-catenin in a complex with nuclear factors
(TCF/ LEF) [21]. However, mutated cases in exons 4 and
5 did not show elevated levels of β-catenin compared to
wild types that may be due to the low number of mu-
tated samples. Although most previous studies were fo-
cused more on exon 3 among HCC patients, the present
study found some unknown mutations in exons 4 and 5
for the first time. However, previous studies reported
mutations in exons 4 and 5 in different cancers of un-
known primary and some cancer cell lines [11, 22–24].
Totally, 18.1% of HCC cases were mutated in the β-
catenin-exon 3; this is the first report from the Middle
East and Iran. This rate was significantly higher in non-
viral HCC rather than HBV-related HCC (29.4% vs
12.7%). Similar findings were reported in most of previ-
ous studies and the rate of mutation in HBV-HCC
ranged from 8 to 19% [15, 25–32], and even higher as
44.1% [9]. Otherwise, this figure among HCV-HCC and/
or non-viral HCC tumors was previously reported in
high levels from 28 to 50% [33–36], being much higher
than our study. Our results appear to be moderately
lower than reports from France [37], Japan [16, 38], Italy
[15] and Europe [28]; however, it should be noted that
HCV is more prevalent in those regions. Additionally,
HBV is the leading cause of HCC in Iran and the Middle
East [39]. Accordingly, it appears that there is a geo-
graphical pattern of CTNNB1 mutation in coordination
with the epidemiologic profile of HBV/HCV as well as
other risk factors such as aflatoxins and alcohol, being
higher in more developed countries rather than develop-
ing and under-developed countries [12, 40].
Furthermore, some studies did not find any CTNNB1
mutation in HBV-HCC tumors [13] or even among
HCC cases with other etiologies among black Africans
[41, 42]. The reason for these intense negative results is
not yet fully understood. However, it is well known that
genetic origin and heterogenecity affect the mutation
rates. Studies have indicated that mutation pattern and
frequencies can be variable according to heterogeneity in
etiology, host genetic and geographical regions [15].
Moreover, among the known driver HCC genes, there is
an obvious different geographical pattern of mutation
for TP53 and RB1 genes that are related to ancestry
genetic [40].
Moreover, we demonstrated that HBV-HCCs had a
unique profile of CTNNB1 mutation pattern; S33C,
H36Q, S37C and A39V were observed mostly in HBV-
HCC, some of them are also reported in previous studies
[29, 43]. Of these, positions at 33 and 37 are the target
phosphorylation sites for GSK3β [21], and H36 increases
the activity of Wnt target genes [7].
Mutations of β-catenin have already been found to be
associated with nuclear accumulation of β-catenin, lead-
ing to transactivation and overexpression of Wnt target
genes including c-Myc, cyclin D1, CTGF, and WISP2 [9,
20, 44]. Therefore, we assessed the activation status of
the Wnt pathway according to the expression level of c-
Myc. Mutations at positions 32 and 45 were mostly re-
lated to elevated levels of c-Myc. However, mutations in
both phosphorylation sites and other sites within the
hotspot region result in upregulation of c-Myc. This
finding is in line with previous studies reporting an ele-
vated level of c-Myc among mutated HCC tumors com-
pared to normal or wild type samples [8, 9, 41].
Functional effects of these mutations were not
Fig. 4 RT-PCR product of β-catenin was resolved in agarose gel, and the intensity of the bands were semi-quantified with GelCount™ software.
Elevated expression of β-catenin in HCC and LC groups was observed in comparison to controls. All the lanes represent the samples tested
Javanmard et al. Infectious Agents and Cancer           (2020) 15:37 Page 7 of 10
previously investigated among clinical samples. Muta-
tions in this region lead to interference in the phosphor-
ylation of β-catenin by the destruction complex (Axin,
APC, CK1, and GSK3-β) and prevent subsequent protea-
somal degradation of β-catenin, resulting in cytoplasmic
accumulation and translocation of β-catenin to the nu-
cleus and activation of the pathway by contributing with
Tcf/Lef transcription factors [20].
Mutations of β-catenin lead to steady activation of the
Wnt pathway, which may occur early in some tumors
[21]. Moreover, higher levels of β-catenin may lead to
the release of this protein from the Axin-APC scaffold
complex [45] and translocation of free molecules to the
nucleus. Thus, elevated levels of β-catenin may lead to
nuclear accumulation of β-catenin and activation of the
pathway. The current study results showed the
overexpression of β-catenin among tumor samples as
well as CTNNB1 mutated cases, being accompanied by
overexpression of c-Myc. Some previous studies also
demonstrated transcriptional dysregulation and overex-
pression of CTNNB1 [9, 46]. This suggests that deregu-
lation of the Wnt pathway begins at the transcription
level, as well as previous findings that β-catenin expres-
sion is in accordance with the protein and mRNA level
[9].
There was an elevated levels of β-catenin and c-Myc
expression in LC group that was associated to HBV in-
fection. This finding was previously described with de-
creased level of serum β-catenin from chronic hepatitis
B, HBV-LC to HBV-HCC [47]. However, no mutation
was found in CTNNB1 among the LC group. This find-
ing suggest that β-catenin mutations and other liver
Fig. 5 Real-time PCR for β-catenin and c-Myc assessed in normalization to the mean expression level of GAPDH and HMBS in adjustment to the
control group. The result showed that the expression of β-catenin and c-Myc was significantly upregulated among cases with known hot spot
mutations (a and b). Among samples with different mutations in exon 3 of the CTNNB1 gene, the level of c-Myc was evaluated in comparison to
the samples with wild type CTNNB1 gene (c). Among samples with a mutation in exons 4–5 of the CTNNB1 gene, the level of c-Myc was
somewhat similar to the wild type (d). *: p < 0.05, **: p < 0.005, ***: p < 0.0005, ****: p < 0.00005
Javanmard et al. Infectious Agents and Cancer           (2020) 15:37 Page 8 of 10
injuries such as cirrhosis are not necessarily cooperative
risk factors of HCC, and so they may independently con-
tribute to the development of HCC [48].
The most important limitation of this study was the
lack of functional tests to assess the effect of viral factors
on the Wnt pathway, as well as in-vivo and in-vitro
based experiments for exact elucidation of HBV-related
up- or downregulation in gene expression.
In conclusion, a significant number of β-catenin muta-
tions were identified in this study that were related to
the overexpression of β-catenin. Overexpression of this
gene was correlated with higher expression of c-Myc as
one of Wnt pathway target genes. Overexpression of β-
catenin and c-Myc in LC appeared to be an earlier event
before development of HBV-HCC. HBV infection was
not involved in the occurrence of mutations in the β-
catenin gene; therefore, dysregulation of the Wnt path-
way may be mediated by the effect of viral factors on
other role players in the pathway. We found some un-
known mutations in exons 4 and 5 of β-catenin that
need further investigations in larger sample sizes to
evaluate of the exact effect.
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